| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 江苏华兰药用新材料股份有限公司成立于1992年，经过多年的不懈努力，现已发展成为一家经济实力雄厚、品种齐全、技术领先、规模优势的专业从事直接接触各类注射剂类药物包装材料的研发制造和销售的国家级高新技术企业。公司主要产品为高中端注射剂的包材用覆膜胶塞、常规胶塞、预灌封活塞、硅胶密封件等药用密封弹性体。 公司拥有国药集团、辉瑞制药、恒瑞医药、齐鲁制药、丽珠医药、扬子江药业、科兴生物、康希诺生物、智飞生物、复星医药、上海医药、广药集团、石药集团等国内外众多知名的药企客户群体，中国医药产业百强榜覆盖率60%以上，同时与全球近40个国家的药企建立了长期稳定的供货关系。在全球新冠疫情爆发期间，为国药集团北京生物、科兴生物、康希诺生物、智飞生物等中国近30家新冠疫苗研发药厂提供新冠疫苗专用密封弹性体，携手药企，为战胜全球新冠疫情贡献中国力量。 在全球药物创新日新月异的研发时代里，作为中国高端注射剂用内包材（胶塞）的开拓者与领跑者，公司致力于成为全球领先的医药用密封弹性体智造者，将一如既往地践行“为药企护航，与健康同行”之使命，时刻不忘“华兰产品等同药品，华兰责任安全有效”之初心，不断提升产品质量，铸造民族品牌，为中国高端注射剂的安全保驾护航！ | ||||||||||||||||||||||||
| Main Business | 直接接触注射剂类药品包装材料的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 华一敏 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 刘雪 | ||||||||||||||||||||||||
| Solicitors | 北京国枫律师事务所 | ||||||||||||||||||||||||
| Auditors | 大华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0510-68951502 | ||||||||||||||||||||||||
| Fax No | 0510-68172226-3326 | ||||||||||||||||||||||||
| Website | www.hlnpm.com | ||||||||||||||||||||||||
| irs@hlnpm.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 01/11/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.875 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.600 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 18.309 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.992B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |